3/25
04:35 pm
itos
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
Low
Report
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
3/6
06:31 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $19.00 to $17.00. They now have an "overweight" rating on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $19.00 to $17.00. They now have an "overweight" rating on the stock.
3/6
11:35 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at JPMorgan Chase & Co. from $22.00 to $15.00. They now have an "overweight" rating on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at JPMorgan Chase & Co. from $22.00 to $15.00. They now have an "overweight" rating on the stock.
3/6
08:12 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
3/5
06:09 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
3/5
07:00 am
itos
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Medium
Report
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
1/16
07:44 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
1/13
07:07 am
itos
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer [Yahoo! Finance]
Low
Report
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer [Yahoo! Finance]
1/10
08:13 pm
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
Low
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.
1/10
07:00 am
itos
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
Medium
Report
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
1/8
07:00 am
itos
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference